文献速递血栓与止血

人血小板抗原1a同种免疫妊娠的自然史:一项前瞻性观察性队列研究

Natural history of human platelet antigen 1a-alloimmunised pregnancies: a prospective observational cohort study.
PubMed 文献 · Lancet Haematol · 2023-10-27

该研究在2017年3月1日至2020年5月1日期间对153106名孕妇进行HPA-1a分型,其中3722名(2.4%)为HPA-1a阴性,913名签署知情同意并纳入。81例HPA-1a同种免疫妊娠中,1例(1.2%)发生严重HPA-1a介导的颅内出血,3例(3.7%)为轻度胎儿新生儿同种免疫性血小板减少症(FNAIT)。作者认为,在无干预情况下,FNAIT严重临床可检测出血的发生率估计为每10000例HPA-1a阴性妊娠中11例(95%CI 0-32)。

要点

  • 153106名孕妇中3722名(2.4%)为HPA-1a阴性,913名纳入研究。
  • 81例HPA-1a同种免疫妊娠中,1例(1.2%)发生严重颅内出血,3例(3.7%)为轻度FNAIT。
  • 81例HPA-1a同种免疫孕妇中73例(90.1%)为HLA-DRB3*01:01阳性。

核心结论

  • 作者认为,在无干预情况下,FNAIT严重临床可检测出血的发生率估计为每10000例HPA-1a阴性妊娠中11例(95%CI 0-32)。
  • 作者认为,严重出血是罕见事件,可能可通过筛查程序预防。

研究设计与样本

  • 前瞻性观察性队列研究,纳入2017年3月1日至2020年5月1日在27周妊娠时接受常规红细胞抗体产前筛查、RhD和Rhc抗原阴性且无年龄限制的孕妇,进行HPA-1a分型。
  • HPA-1a阴性孕妇检测HPA同种抗体,医护人员对全部检测结果设盲。
  • 主要结局为严重临床可检测FNAIT的比例,定义为妊娠期间或出生后第一周内观察到颅内出血、器官出血或出血相关死亡;未归类为严重的临床可检测FNAIT归类为轻度。
  • 153106名孕妇行HPA-1a分型,3722名(2.4%)为HPA-1a阴性;913名HPA-1a阴性孕妇签署知情同意、接受HPA-1a抗体筛查并纳入研究。
  • 85名HPA-1a阴性参与者检出抗HPA-1a抗体,排除3名胎儿为HPA-1a阴性者和1名既往有FNAIT患儿者;纳入对照包括820例HPA-1a阴性未免疫妊娠和2704例随机选取的RhD和Rhc阴性且HPA-1a分型阳性孕妇。

主要发现

  • 81例胎儿中,1例(1.2%)诊断为严重HPA-1a介导的颅内出血,3例(3.7%)为轻度FNAIT。
  • 81例HPA-1a同种免疫孕妇中73例(90.1%)为HLA-DRB3*01:01阳性。
  • 孕次和产次似乎不是HPA-1a同种免疫的危险因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare disease that untreated can lead to intracranial haemorrhage or death. The natural history of FNAIT is still unclear; therefore, the benefits of screening cannot be estimated and no routine screening is yet in place. We aimed to assess the incidence of clinically detectable FNAIT among pregnancies in human platelet antigen-1a (HPA-1a)-immunised women. METHODS: We did a prospective observational cohort study of pregnant women negative for rhesus D (RhD) and rhesus c (Rhc) antigens, without age limits, who underwent routine antenatal screening for red cell antibodies at 27 weeks' gestation and were typed for HPA-1a between March 1, 2017, and May 1, 2020. HPA-1a-negative women were tested for HPA alloantibodies. Health-care professionals were masked to all test results. The main outcome was the proportion of neonates with severe, clinically detectable FNAIT, defined as having an intracranial bleed, organ bleed, or bleeding-related death observed during pregnancy or within the first week of life. Cases of clinically detectable FNAIT not categorised as severe were categorised as mild. This study is registered with ClinicalTrials.gov (NCT04067375). FINDINGS: Of 153 106 women typed for HPA-1a, 3722 (2·4%) were negative for HPA-1a. 913 HPA-1a-negative women gave informed consent, underwent HPA-1a antibody screening, and were included in the study. Anti-HPA-1a antibodies were detected in 85 HPA-1a-negative participants, among whom three with HPA-1a-negative fetuses and one with a previous child with FNAIT were excluded. As controls, 820 HPA-1a-negative, non-immunised pregnancies and 2704 randomly selected pregnancies of women negative for RhD and Rhc who were typed HPA-1a positive were included. Of 81 fetuses included, one (1·2%) was diagnosed with severe HPA-1a-mediated intracranial haemorrhage and three (3·7%) had mild FNAIT. Gravidity and parity did not seem to be risk factors for HPA-1a immunisation. 73 (90·1%) of 81 HPA-1a-immunised women were positive for HLA-DRB3*01:01. INTERPRETATION: Our data suggest that, without intervention, the incidence of major clinically detectable bleeding in FNAIT is estimated as 11 (95% CI 0-32) per 10 000 HPA-1a-negative pregnancies. These findings imply that severe bleeding is a rare event that potentially could be prevented by a screening programme. FUNDING: Landsteiner Foundation for Blood Transfusion Research and Sanquin.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. de Vos TW, Winkelhorst D, Porcelijn L, et al. Natural history of human platelet antigen 1a-alloimmunised pregnancies: a prospective observational cohort study. Lancet Haematol. 2023. PMID: 38407610. doi:10.1016/S2352-3026(23)00271-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。